Applied Therapeutics, Inc., a biopharmaceutical company, develops novel products to target cardiovascular disease, galactosemia, and diabetic complications. Its lead product candidate is AT-001 that is in phase II clinical trials for treating diabetic cardiomyopathy, as well as is in phase I clinical trials to treat diabetic peripheral neuropathy. The company's preclinical stage products include AT-001 for acute myocardial infraction; AT-007 for treating galactosemia; AT-003 to treat diabetic retinopathy; and AT-104 for the treatment of orphan hematological oncology. Applied Therapeutics, Inc. was founded in 2016 and is headquartered in New York, New York.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone212-220-9226
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees4
Next Earnings Date11/11/2019 (Estimated)
OptionableNot Optionable
Applied Therapeutics (NASDAQ:APLT) Frequently Asked Questions
What is Applied Therapeutics' stock symbol?
Applied Therapeutics trades on the NASDAQ under the ticker symbol "APLT."
How were Applied Therapeutics' earnings last quarter?
Applied Therapeutics (NASDAQ:APLT) announced its quarterly earnings data on Monday, August, 12th. The company reported ($0.60) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.48) by $0.12. View Applied Therapeutics' Earnings History.
When is Applied Therapeutics' next earnings date?
What price target have analysts set for APLT?
4 brokers have issued 12 month price targets for Applied Therapeutics' shares. Their forecasts range from $24.00 to $29.00. On average, they anticipate Applied Therapeutics' share price to reach $26.50 in the next year. This suggests a possible upside of 160.8% from the stock's current price. View Analyst Price Targets for Applied Therapeutics.
What is the consensus analysts' recommendation for Applied Therapeutics?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Applied Therapeutics in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Applied Therapeutics.
Has Applied Therapeutics been receiving favorable news coverage?
Media headlines about APLT stock have trended negative recently, InfoTrie Sentiment Analysis reports. InfoTrie identifies negative and positive news coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Applied Therapeutics earned a news impact score of -2.8 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the company's share price in the near future. View News Stories for Applied Therapeutics.
Are investors shorting Applied Therapeutics?
Applied Therapeutics saw a increase in short interest in September. As of September 30th, there was short interest totalling 60,800 shares, an increase of 406.7% from the August 30th total of 12,000 shares. Based on an average trading volume of 16,200 shares, the days-to-cover ratio is presently 3.8 days. Approximately 0.8% of the shares of the stock are short sold. View Applied Therapeutics' Current Options Chain.
Who are some of Applied Therapeutics' key competitors?
Some companies that are related to Applied Therapeutics include Vanda Pharmaceuticals (VNDA), ZIOPHARM Oncology (ZIOP), Vectura Group (VEGPF), Principia Biopharma (PRNB), Stoke Therapeutics (STOK), Wave Life Sciences (WVE), Cytokinetics (CYTK), Advanz Pharma (CXRXF), Axsome Therapeutics (AXSM), Homology Medicines (FIXX), Kura Oncology (KURA), Karyopharm Therapeutics (KPTI), Rocket Pharmaceuticals (RCKT), NextCure (NXTC) and Arvinas (ARVN).
What other stocks do shareholders of Applied Therapeutics own?
Who are Applied Therapeutics' key executives?
Applied Therapeutics' management team includes the folowing people:
- Dr. Shoshana Shendelman Ph.D., Chairman, Founder, Pres, CEO & Sec. (Age 40)
- Dr. Mark Joseph Vignola, Chief Financial Officer (Age 42)
- Dr. Riccardo Perfetti, Chief Medical Officer (Age 59)
When did Applied Therapeutics IPO?
(APLT) raised $60 million in an IPO on the week of May 13th 2019. The company issued 4,000,000 shares at $14.00-$16.00 per share. Citigroup, Cowen and UBS Investment Bank acted as the underwriters for the IPO and Baird was co-manager.
When does the company's lock-up period expire?
Applied Therapeutics' lock-up period expires on Monday, November 11th. Applied Therapeutics had issued 4,000,000 shares in its public offering on May 14th. The total size of the offering was $40,000,000 based on an initial share price of $10.00. After the end of the company's lock-up period, major shareholders and company insiders will be able to sell their shares of the company.
How do I buy shares of Applied Therapeutics?
Shares of APLT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Applied Therapeutics' stock price today?
One share of APLT stock can currently be purchased for approximately $10.16.
How big of a company is Applied Therapeutics?
What is Applied Therapeutics' official website?
How can I contact Applied Therapeutics?
Applied Therapeutics' mailing address is 340 MADISON AVENUE 19TH FLOOR, NEW YORK NY, 10173. The company can be reached via phone at 212-220-9226 or via email at [email protected]
MarketBeat Community Rating for Applied Therapeutics (NASDAQ APLT)
MarketBeat's community ratings are surveys of what our community members think about Applied Therapeutics and other stocks. Vote "Outperform" if you believe APLT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe APLT will underperform the S&P 500 over the long term. You may vote once every thirty days.
